CD274 and cancer: In addition, Sen et al. [137] reported that SRA737 and anti-PD-L1 combination therapy significantly decreased the population of myeloid-derived suppressor cells and immunosuppressive M2 macrophages and increased the expression of CCL5, CXCL10, and IFN-β, which enhances the anti-cancer immune response in multiple cancer cells.